Cargando…
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
BACKGROUND: Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments for 5-FU associated coronary vasospam. Our objective was to assess the safety and efficacy of re-challenge with 5-FU after pre-tre...
Autores principales: | Zafar, Amna, Drobni, Zsofia D., Lei, Matthew, Gongora, Carlos A., Quinaglia, Thiago, Lou, Uvette Y., Mosarla, Ramya, Murphy, Sean P., Jones-O’Connor, Maeve, Mahmood, Ali, Hartmann, Sarah, Gilman, Hannah K., Weekes, Colin D., Nipp, Ryan, Clark, John R., Clark, Jeffrey W., Blaszkowsky, Lawrence S., Tavares, Erica, Neilan, Tomas G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989300/ https://www.ncbi.nlm.nih.gov/pubmed/35390017 http://dx.doi.org/10.1371/journal.pone.0265767 |
Ejemplares similares
-
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm
por: Zafar, Amna, et al.
Publicado: (2021) -
Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021) -
Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy
por: Lee, Charlotte, et al.
Publicado: (2022) -
5-Fluorouracil–Induced Coronary Vasospasm
por: Arya, Sumedha, et al.
Publicado: (2018) -
Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)